Letters

Postmarketing surveillance

BMJ 1994; 309 doi: http://dx.doi.org/10.1136/bmj.309.6948.194a (Published 16 July 1994) Cite this as: BMJ 1994;309:194
  1. S Voss,
  2. F Harris
  1. Southampton and South West Hampshire Health Commission, Southampton SO16 4GX
  2. North and Mid Hampshire Health Commission, Basingstoke RG24 9NB.

    EDITOR, - The need to monitor the safety of medicines as they are used in clinical practice is well recognised and based on the Committee on the Safety of Medicines' yellow card system. Further evidence of drug safety is provided by the Drug Safety Research Unit's prescription event monitoring system1 and postmarketing surveillance performed by pharmaceutical companies or by …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe